Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Co-administration of pramlintide and insulin via an automated dual hormone artificial pancreas system to regulate glucose levels in adults with type 1 diabetes

FY 2022-23

Summary
Type 1 diabetes is a chronic disease caused by the autoimmune destruction of pancreatic beta-cells responsible for the release of various hormones, including insulin, that control one’s plasma glucose levels. Closed-loop systems are a promising therapy choice for patients with type 1 diabetes. The closed-loop system is composed of three components: glucose sensor, an infusion pump, and a dosing algorithm that controls how much insulin is delivered based on the sensor readings. In my research project, I also investigate the administration of Pramlintide which is a synthetic analog of the hormone Amylin which contributes to regulating glucose levels by delaying gastric emptying and increasing satiety. I aim to conduct a randomized, controlled, open-label, crossover trial to compare our novel rapid insulin-and-pramlintide artificial pancreas with rapid insulin-and-placebo artificial pancreas in adults with type 1 diabetes in an outpatient, free-living, unsupervised setting. I hypothesize that the rapid insulin (lispro or aspart)-and-pramlintide artificial pancreas will improve glucose control compared to insulin-and-placebo artificial pancreas.The trial will enroll 26 adults (= 18 years of age) with type 1 diabetes who meet the eligibility criteria. Each participant completes 4 weeks of each intervention (order: block randomization) separated by 14-30 days of washout period. The automated insulin delivery system will automatically and wirelessly adjust the pumps’ basal insulin and pramlintide rates every 10 minutes, in response to participants’ glucose levels. Pramlintide will be infused in a second pump at a fixed ratio of 0.6 units per 1 unit of insulin for the full 4-week intervention.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
500273
Name
El Maalouli Jimmy
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Co-administration of pramlintide and insulin via an automated dual hormone artificial pancreas system to regulate glucose levels in adults with type 1 diabetes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Artificial Pancreas; Dexcom G6 Glucose Sensor; Diabetic Ketoacidosis (Dka); Dosing Algorithm; Hyperglycemia; Hypoglycemia; Insulin Basal And Bolus; Pramlintide; Rapid Insulin; Ypsopump
Abstract
Type 1 diabetes is a chronic disease caused by the autoimmune destruction of pancreatic beta-cells responsible for the release of various hormones, including insulin, that control one’s plasma glucose levels. Closed-loop systems are a promising therapy choice for patients with type 1 diabetes. The closed-loop system is composed of three components: glucose sensor, an infusion pump, and a dosing algorithm that controls how much insulin is delivered based on the sensor readings. In my research project, I also investigate the administration of Pramlintide which is a synthetic analog of the hormone Amylin which contributes to regulating glucose levels by delaying gastric emptying and increasing satiety. I aim to conduct a randomized, controlled, open-label, crossover trial to compare our novel rapid insulin-and-pramlintide artificial pancreas with rapid insulin-and-placebo artificial pancreas in adults with type 1 diabetes in an outpatient, free-living, unsupervised setting. I hypothesize that the rapid insulin (lispro or aspart)-and-pramlintide artificial pancreas will improve glucose control compared to insulin-and-placebo artificial pancreas.The trial will enroll 26 adults (= 18 years of age) with type 1 diabetes who meet the eligibility criteria. Each participant completes 4 weeks of each intervention (order: block randomization) separated by 14-30 days of washout period. The automated insulin delivery system will automatically and wirelessly adjust the pumps’ basal insulin and pramlintide rates every 10 minutes, in response to participants’ glucose levels. Pramlintide will be infused in a second pump at a fixed ratio of 0.6 units per 1 unit of insulin for the full 4-week intervention.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
El Maalouli, Jimmy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~